Sunshine Biopharma Inc Stock Price, News & Analysis

Sunshine Biopharma (NASDAQ:SBFM) outlines a multi‑pronged growth strategy combining generics, biosimilars, pipeline programs, and a new digital treasury position.

Key facts: $5.0M invested in a digital treasury asset, Q1 revenue $8.9M (+18% YoY), Q2 revenue $9.41M, Q1 gross profit $2.73M, Q1 net loss $1.18M, and an Aegis Capital BUY with a $7.00 price target on October 14, 2025.

Preclinical programs include a K1.1 mRNA therapy with tumor suppression signals and antiviral protease inhibitors developed with the University of Arizona.

Sunshine Biopharma (NASDAQ:SBFM) on October 14, 2025 described multi‑axis execution across generics, biosimilars, mRNA cancer therapies, and antiviral research.

Key points: Nora Pharma expanded generics including gabapentin; NIOPEG biosimilar to Neulasta launched July 2; first‑quarter revenue was $8.9M (+18% YoY) with gross profit $2.73M and net loss $1.18M; second‑quarter revenue was $9.41M; the company added a $5M digital treasury asset; mRNA candidate K1.1 showed tumor reduction in preclinical liver models; antiviral PLpro inhibitors showed dose‑dependent activity against SARS‑CoV‑2.

Sunshine Biopharma (NASDAQ:SBFM) announced on October 14, 2025 that its Board approved a $5 million strategic investment in Bitcoin (BTC) as a treasury reserve asset.

The Company said the $5 million position will be acquired over time via a regulated digital asset custodian or by buying an ETF or proxy stock, and that it may allocate additional funds to increase Bitcoin holdings in the future. Management framed the move as a hedge and a high-conviction asset to strengthen the company's financial foundation while continuing focus on its drug development pipeline, including antiviral small molecules and mRNA-based cancer therapies.

Sunshine Biopharma (NASDAQ:SBFM) and the University of Arizona announced a new series of orally active, non‑covalent PLpro protease inhibitors that show dose‑dependent antiviral activity in mice infected with SARS‑CoV‑2. The compounds are potent against the PLpro enzyme, exhibited dose‑dependent efficacy in cellular SARS‑CoV‑2 models, and displayed favorable pharmacokinetic profiles in mice, rats and dogs. The program follows an initial PLpro library published in August 2024 in Journal of Medicinal Chemistry. Ongoing work includes dose‑dependent efficacy analysis in infected mice and further preclinical evaluation.

Sunshine Biopharma (NASDAQ:SBFM) has announced the launch of NIOPEG®, its first biosimilar drug, through its Canadian subsidiary Nora Pharma. NIOPEG® is comparable to NEULASTA® (Pegfilgrastim) and is designed to reduce infection risk in chemotherapy patients with non-myeloid malignancies.

The global market for NEULASTA® and its biosimilars was valued at $4.5 billion in 2024, with projections to reach $9.2 billion by 2033, growing at a CAGR of 8.5%. In Canada, where biologic drug sales reached $10 billion in 2020, the market represents a significant opportunity due to high per capita biologics spending and favorable provincial switching policies.

Sunshine Biopharma (NASDAQ:SBFM) announced that its Canadian subsidiary, Nora Pharma Inc., has launched generic Gabapentin, an anticonvulsant medication for treating neuropathic pain and epilepsy. The drug, available in 100mg, 300mg, and 400mg capsules, is a generic version of Neurontin®. The global Gabapentin market, valued at $1.92 billion in 2024, is projected to reach $3.07 billion by 2030, driven by increasing neurological disorders, expanding applications, shift from opioids, and aging population. Canada represents 1.2% of the global Gabapentin market. The company aims to strengthen its position in Canada's generic drugs market, which is expected to grow from $9.4 billion to $19.2 billion by 2032.

Sunshine Biopharma (NASDAQ:SBFM) reported its Q1 2025 financial results, showing revenue growth of 18% to $8.9 million compared to $7.5 million in Q1 2024. The company's gross profit increased to $2.7 million, while net loss decreased to $1.18 million from $1.28 million year-over-year. Key operational highlights include the appointment of Michel Roy as Chief Commercial Officer and the launch of 6 new generic prescription drugs. The company also made progress in its research, completing additional studies on its K1.1 mRNA Lipid Nanoparticle product for hepatocellular carcinoma treatment. Despite revenue growth, the company continues to operate at a loss with increased G&A expenses of $4.03 million.

Sunshine Biopharma (NASDAQ:SBFM) has announced the launch of generic Lurasidone through its Canadian subsidiary Nora Pharma. The drug, a generic version of Latuda®, is designed for treating schizophrenia and bipolar depression. Available in 20mg, 40mg, 60mg, and 80mg strengths, the medication comes in 30-tablet bottles. The global Lurasidone market, valued at $1.2 billion in 2024, is projected to reach $2.5 billion by 2033, growing at an 8.01% CAGR. While Canada represents 2.2% of the global pharmaceutical market, it ranks as the eighth-largest pharmaceutical market globally. The Canadian generic drugs market, currently at $9.4 billion, is expected to reach $19.2 billion by 2032.

Sunshine Biopharma (NASDAQ:SBFM) has announced the launch of Everolimus, a generic oncology drug, in the Canadian market through its subsidiary Nora Pharma Inc. Everolimus, a generic equivalent of Afinitor®, is designed to treat multiple conditions including advanced renal cell carcinoma, HER2-negative breast cancer, neuroendocrine tumors, and subependymal giant cell astrocytoma.

The drug is available in 2.5 mg, 5 mg, and 10 mg strengths in 30-tablet blister packs. The global Everolimus market, valued at $2.5 billion in 2023, is projected to reach $4.8 billion by 2032 with a 7.1% CAGR. The Canadian market segment represents approximately 2.2% of the global market and is growing at a 6.4% CAGR.